ongoing trials trial from www.clinicaltrials.gov Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations - Phase 2 - Not yet recruiting Year: 2022 Date: December 2022 Author: Aceragen Source https://ClinicalTrials.gov/show/NCT05641298 Study design (if review, criteria of inclusion for studies) Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment Participants Cystic Fibrosis|Cystic Fibrosis Pulmonary Exacerbation - 12 Years and older (Child, Adult, Older Adult) Interventions Drug: Sodium Fusidate|Drug: Placebo Outcome measures Desirability in outcome ranking (DOOR)